Assessment of Fatigue in Head and Neck Cancer Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy: A Prospective Observational Study

Assessment of Fatigue in Head and Neck Cancer Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy: A Prospective Observational Study - Fatigue trial

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060574

Enrollment

100

Registered

2026-02-10

Start date

2025-12-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with head and neck cancer who received cisplatin-based concurrent chemoradiotherapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: i) Histological or cytological confirmation of head and neck cancer. ii) Scheduled to complete cisplatin-based concurrent chemoradiotherapy. iii) Able to understand written Japanese. iv) Provided written informed consent after receiving a full explanation of the study.

Exclusion criteria

Exclusion criteria: i) Planned to receive subsequent treatment after chemoradiotherapy for head and neck cancer. ii) Treated with radiotherapy alone (without concurrent chemotherapy). iii) Deemed inappropriate for participation in this study by the attending physician.

Design outcomes

Primary

Measure	Time frame
Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale	—

Secondary

Measure	Time frame
Comprehensive quality-of-life assessment using the EORTC QLQ-C30	—

Countries

Japan

Contacts

Public ContactHideki Tanaka

Tokyo Medical University Department of Otorhinolaryngology, Head and Neck Surgery

hidekich@tokyo-med.ac.jp03-3342-6111

Outcome results